title: Features and prognoses of infantile patients with atopic dermatitis hospitalized for severe complications.
abstract: Although atopic dermatitis (AD) itself is regarded as a non-life threatening disease, childhood AD may be rarely accompanied by some serious complications. Six infantile AD patients who were hospitalized because of severe systemic complications, in addition to severe dermatitis on almost the entire body surface, are described. They were complicated by hypoproteinemia, hypovolemia, thrombocytosis, reduced serum immunoglobulin G, elevated serum liver enzymes and growth retardation. They had not been treated with topical corticosteroid before hospitalization. They were treated with topical corticosteroid and their eruption remarkably improved within 20 days (median) of hospitalization. Most of the abnormal clinical data including platelet numbers, serum levels of total protein, and liver enzymes had become normal at the day of discharge. After 30 +/- 4 months of follow up, their skin condition was fair with daily application of moisturizer and occasional use of topical corticosteroid, without any systemic problems. Although severe infantile AD may be accompanied by potentially life-threatening systemic complications, their prognoses concerning AD are favorable if they are treated adequately from the beginning of their infancy.
authors.affiliation: Department of Dermatology, Kyoto Prefectural University of Medicine Graduatw School of Medical Science, Kamigyo-ku, Kyoto, Japan. nkatoh@koto.kpu-m.ac.jp
authors.forename: Norito
authors.initials: N
authors.lastname: Katoh
authors.forename: Hajime
authors.initials: H
authors.lastname: Hosoi
authors.forename: Tohru
authors.initials: T
authors.lastname: Sugimoto
authors.forename: Saburo
authors.initials: S
authors.lastname: Kishimoto
mesh_terms: D000279:Administration, Cutaneous; D000410:Alanine Transaminase / Q000097:blood; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D003876:Dermatitis, Atopic / Q000097:blood / Q000145:classification / Q000150:complications*; D003879:Dermatologic Agents / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000209:etiology; D006760:Hospitalization; D006801:Humans; D007019:Hypoproteinemia / Q000209:etiology; D020896:Hypovolemia / Q000209:etiology; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D008099:Liver / Q000201:enzymology; D008297:Male; D010976:Platelet Count; D011239:Prednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D011379:Prognosis; D012709:Serum Albumin / Q000032:analysis; D013922:Thrombocytosis / Q000209:etiology
chemical_list: D000893:Anti-Inflammatory Agents; D001798:Blood Proteins; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D012709:Serum Albumin; C023724:acepreval; D011239:Prednisolone; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase